Pioneering the future of joint health
We are a clinical-stage biotechnology company developing MOTYS™, a Phase 3 ready intra-articular biologic delivering potent anti-inflammatory and regenerative capabilities for osteoarthritis.
We are a clinical-stage biotechnology company developing MOTYS™, a Phase 3 ready intra-articular biologic delivering potent anti-inflammatory and regenerative capabilities for osteoarthritis.
At Doron Therapeutics, we're pioneering a new approach to treating osteoarthritis—one of the most common and debilitating joint disorders affecting millions worldwide.
Our lead product, MOTYS™, represents a paradigm shift in osteoarthritis treatment. Derived from placental tissue and rich in beneficial growth factors, MOTYS™ delivers consistent, powerful anti-inflammatory, tissue-protective, and regenerative effects.
The name MOTYS™ comes from the Latin word motus, meaning motion—reflecting our commitment to helping people regain the freedom of movement that osteoarthritis takes away.
Read our story
MOTYS™ works through three complementary pathways to address the root causes of osteoarthritis
Reduces joint inflammation by modulating key inflammatory pathways, providing relief from pain and swelling.
Protects existing cartilage tissue from further degradation, slowing disease progression.
Stimulates regeneration of cartilage tissue, promoting natural healing and repair processes.
Whether you're a physician, researcher, investor, or patient advocate, we'd love to hear from you.